P50MH129699
Project Grant
Overview
Grant Description
Center for Suicide Research and Prevention - Suicide is one of the leading causes of death worldwide and the 10th leading cause of death in the US. A major barrier to suicide prevention has been that the cutting-edge scientific advances that have occurred in the past few decades have not yet been translated and implemented into clinical practice settings.
We propose the development of a practice-based Center for Suicide Research and Prevention (CSRP) that will support the development, deployment, and evaluation of practice-ready and deployment-focused interventions aimed at improving the identification and effective treatment of those at risk of suicide. This center will be a collaborative effort between researchers, clinicians, and stakeholders at Mass General Brigham (MGB) and Harvard University.
Our focus is on improving the identification and prevention of suicide-related behaviors (SRBs) among patients presenting for treatment at emergency departments (EDs) and psychiatric inpatient units. Decades of research have shown that 50% of people who die by suicide are seen in a healthcare setting within one month before their death, 40% visit an ED the year before their death, and the suicide rate is highest in the weeks immediately following discharge from a psychiatric inpatient hospitalization.
Our first aim is to build and maintain a cohesive and innovative transdisciplinary center dedicated to advancing suicide prevention. This will be accomplished via the work of our proposed Administrative Core and Methods Core.
Our second aim is to conduct four practice-focused research projects that target prediction and prevention of suicidal behaviors in ED and inpatient settings. Our Signature Project (SIG) will implement a previously-developed machine learning prediction algorithm based on electronic health record (EHR) and self-report data collected in the ED and randomly assign the clinicians of 4,000 patients to receive (experimental condition) or not receive (control condition) the predicted probability that their patient will make a suicide attempt after ED discharge. We will test the impact of this intervention on the suicide attempt rate and clinician decision-making. The SIG also will examine clinician acceptability and adherence, prediction model improvement, and the development of treatment optimization rules regarding patients' likelihood of benefiting from hospitalization versus alternative treatments.
Our three exploratory projects (EXP): (EXP1) will use the SIG prediction model to identify ED patients at risk of suicidal behavior and experimentally test the effectiveness of an enhanced outreach intervention administered in collaboration with a community partner - Samaritans of Boston; (EXP2) will implement and test EHR-based risk algorithms in two inpatient units with a special focus on the use of social determinants of health to improve prediction among under-represented adolescents; and (EXP3) will test a just-in-time adaptive intervention using an innovative micro-randomized trial design to connect at-risk patients with care when needed most.
The third aim of the center is to support education, dissemination, and implementation efforts that will have a significant and sustained effect on suicide prevention.
We propose the development of a practice-based Center for Suicide Research and Prevention (CSRP) that will support the development, deployment, and evaluation of practice-ready and deployment-focused interventions aimed at improving the identification and effective treatment of those at risk of suicide. This center will be a collaborative effort between researchers, clinicians, and stakeholders at Mass General Brigham (MGB) and Harvard University.
Our focus is on improving the identification and prevention of suicide-related behaviors (SRBs) among patients presenting for treatment at emergency departments (EDs) and psychiatric inpatient units. Decades of research have shown that 50% of people who die by suicide are seen in a healthcare setting within one month before their death, 40% visit an ED the year before their death, and the suicide rate is highest in the weeks immediately following discharge from a psychiatric inpatient hospitalization.
Our first aim is to build and maintain a cohesive and innovative transdisciplinary center dedicated to advancing suicide prevention. This will be accomplished via the work of our proposed Administrative Core and Methods Core.
Our second aim is to conduct four practice-focused research projects that target prediction and prevention of suicidal behaviors in ED and inpatient settings. Our Signature Project (SIG) will implement a previously-developed machine learning prediction algorithm based on electronic health record (EHR) and self-report data collected in the ED and randomly assign the clinicians of 4,000 patients to receive (experimental condition) or not receive (control condition) the predicted probability that their patient will make a suicide attempt after ED discharge. We will test the impact of this intervention on the suicide attempt rate and clinician decision-making. The SIG also will examine clinician acceptability and adherence, prediction model improvement, and the development of treatment optimization rules regarding patients' likelihood of benefiting from hospitalization versus alternative treatments.
Our three exploratory projects (EXP): (EXP1) will use the SIG prediction model to identify ED patients at risk of suicidal behavior and experimentally test the effectiveness of an enhanced outreach intervention administered in collaboration with a community partner - Samaritans of Boston; (EXP2) will implement and test EHR-based risk algorithms in two inpatient units with a special focus on the use of social determinants of health to improve prediction among under-represented adolescents; and (EXP3) will test a just-in-time adaptive intervention using an innovative micro-randomized trial design to connect at-risk patients with care when needed most.
The third aim of the center is to support education, dissemination, and implementation efforts that will have a significant and sustained effect on suicide prevention.
Awardee
Funding Goals
THE MISSION OF THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) IS TO TRANSFORM THE UNDERSTANDING AND TREATMENT OF MENTAL ILLNESSES THROUGH BASIC AND CLINICAL RESEARCH, PAVING THE WAY FOR PREVENTION, RECOVERY, AND CURE. IN MAY 2020, NIMH RELEASED ITS NEW STRATEGIC PLAN FOR RESEARCH. THE NEW STRATEGIC PLAN BUILDS ON THE SUCCESSES OF PREVIOUS NIMH STRATEGIC PLANS BY PROVIDING A FRAMEWORK FOR SCIENTIFIC RESEARCH AND EXPLORATION, AND ADDRESSING NEW CHALLENGES IN MENTAL HEALTH. THE NEW STRATEGIC PLAN OUTLINES FOUR HIGH-LEVEL GOALS: GOAL 1: DEFINE THE BRAIN MECHANISMS UNDERLYING COMPLEX BEHAVIORS GOAL 2: EXAMINE MENTAL ILLNESS TRAJECTORIES ACROSS THE LIFESPAN GOAL 3: STRIVE FOR PREVENTION AND CURES GOAL 4: STRENGTHEN THE PUBLIC HEALTH IMPACT OF NIMH-SUPPORTED RESEARCH THESE FOUR GOALS FORM A BROAD ROADMAP FOR THE INSTITUTE'S RESEARCH PRIORITIES OVER THE NEXT FIVE YEARS, BEGINNING WITH THE FUNDAMENTAL SCIENCE OF THE BRAIN AND BEHAVIOR, AND EXTENDING THROUGH EVIDENCE-BASED SERVICES THAT IMPROVE PUBLIC HEALTH OUTCOMES. THE INSTITUTE'S OVERALL FUNDING STRATEGY IS TO SUPPORT A BROAD SPECTRUM OF INVESTIGATOR-INITIATED RESEARCH IN FUNDAMENTAL SCIENCE, WITH INCREASING USE OF INSTITUTE-SOLICITED INITIATIVES FOR APPLIED RESEARCH WHERE PUBLIC HEALTH IMPACT IS A SHORT-TERM MEASURE OF SUCCESS. THE NEW STRATEGIC PLAN ALSO ADDRESSES A NUMBER OF CROSS-CUTTING THEMES THAT ARE RELEVANT TO ALL RESEARCH SUPPORTED BY NIMH, THESE THEMES HIGHLIGHT AREAS WHERE NIMH-FUNDED SCIENCE MAY HAVE THE GREATEST IMPACT, BRIDGE GAPS, AND OFFER NOVEL APPROACHES TO ACCELERATE ADVANCES IN MENTAL HEALTH RESEARCH. FOR EXAMPLE, NIMH VALUES A COMPREHENSIVE RESEARCH AGENDA THAT TAKES AN INCLUSIVE APPROACH THAT ENSURES RESEARCH INTERESTS ARE VARIED, MAINTAIN DIVERSE PARTICIPATION AND PARTNERSHIPS, AND ACHIEVE RESEARCH GOALS ACROSS MULTIPLE TIMEFRAMES. THIS INCLUDES DIVERSE METHODOLOGIES, TOOLS, AND MODELS, RESEARCH ADDRESSING COMPLEX BASIC, TRANSLATIONAL, AND APPLIED QUESTIONS, RESEARCH INCLUDING BOTH SEXES AND, AS APPROPRIATE, GENETIC BACKGROUND, AND, PARTICIPANTS FROM DIVERSE RACIAL AND ETHNIC BACKGROUNDS, AND ACROSS GENDER IDENTITIES, GEOGRAPHICAL CONTEXT, SOCIOECONOMIC STATUS, NEUROTYPE, AND AGE OFFERING THE BEST POSSIBLE REPRESENTATION, FOR THE BROADEST NUMBER OF INDIVIDUALS WHO MAY ULTIMATELY BENEFIT FROM THESE SCIENTIFIC ADVANCES. TO ACCOMPLISH THE GOALS OUTLINED IN THE NEW STRATEGIC PLAN, NIMH WILL SUPPORT RESEARCH THAT AIMS: TO CHARACTERIZE THE GENOMIC, MOLECULAR, CELLULAR, AND CIRCUIT COMPONENTS CONTRIBUTING TO BRAIN ORGANIZATION AND FUNCTION, TO IDENTIFY THE DEVELOPMENTAL, FUNCTIONAL, AND REGULATORY MECHANISMS RELEVANT TO COGNITIVE, AFFECTIVE, AND SOCIAL DOMAINS, ACROSS UNITS OF ANALYSIS, AND, TO GENERATE AND VALIDATE NOVEL TOOLS, TECHNIQUES, AND MEASURES TO QUANTIFY CHANGES IN THE ACTIVITY OF MOLECULES, CELLS, CIRCUITS, AND CONNECTOMES. TO DISCOVER GENE VARIANTS AND OTHER GENOMIC ELEMENTS THAT CONTRIBUTE TO THE DEVELOPMENT OF MENTAL ILLNESSES IN DIVERSE POPULATIONS, TO ADVANCE OUR UNDERSTANDING OF THE COMPLEX ETIOLOGY OF MENTAL ILLNESSES USING MOLECULAR EPIDEMIOLOGIC APPROACHES THAT INCORPORATE INDIVIDUAL GENETIC INFORMATION IN LARGE COHORTS, TO ELUCIDATE HOW HUMAN GENETIC VARIATION AFFECTS THE COORDINATION OF MOLECULAR, CELLULAR, AND PHYSIOLOGICAL NETWORKS SUPPORTING HIGHER-ORDER FUNCTIONS AND EMERGENT PROPERTIES OF NEUROBIOLOGICAL SYSTEMS, AND, TO DEVELOP NOVEL TOOLS AND TECHNIQUES FOR THE ANALYSIS OF LARGE-SCALE GENETIC, MULTI-OMIC DATA AS IT APPLIES TO MENTAL HEALTH. TO UTILIZE CONNECTOMIC APPROACHES TO IDENTIFY BRAIN NETWORKS AND CIRCUIT COMPONENTS THAT CONTRIBUTE TO VARIOUS ASPECTS OF MENTAL FUNCTION AND DYSFUNCTION, TO DETERMINE THROUGH BRAIN-WIDE ANALYSIS HOW CHANGES IN THE PHYSIOLOGICAL PROPERTIES OF MOLECULES, CELLS, AND CIRCUITS CONTRIBUTE TO MENTAL ILLNESSES, TO DEVELOP MOLECULAR, CELLULAR, AND CIRCUIT-LEVEL BIOMARKERS OF IMPAIRED NEURAL FUNCTION IN HUMANS, AND, TO DEVELOP INNOVATIVE TECHNOLOGIES, INCLUDING NEW IMAGING, COMPUTATIONAL, PHARMACOLOGICAL, AND GENETIC TOOLS TO INTERROGATE AND MODULATE CIRCUIT ACTIVITY AND STRUCTURE ALTERED IN MENTAL ILLNESSES. TO ELUCIDATE THE MECHANISMS CONTRIBUTING TO THE TRAJECTORIES OF BRAIN DEVELOPMENT AND BEHAVIOR, AND, TO CHARACTERIZE THE EMERGENCE AND PROGRESSION OF MENTAL ILLNESSES, AND IDENTIFYING SENSITIVE PERIODS FOR OPTIMAL INTERVENTION. TO DETERMINE EARLY RISK AND PROTECTIVE FACTORS, AND RELATED MECHANISMS, TO SERVE AS NOVEL INTERVENTION GROUPS, AND, TO DEVELOP RELIABLE AND ROBUST BIOMARKERS AND ASSESSMENT TOOLS TO PREDICT ILLNESS ONSET, COURSE, AND ACROSS DIVERSE POPULATIONS. TO DEVELOP NOVEL INTERVENTIONS USING A MECHANISM-INFORMED, EXPERIMENTAL THERAPEUTICS APPROACH, AND, TO DEVELOP AND IMPLEMENT MEASUREMENT STRATEGIES TO FACILITATE MECHANISM-BASED INTERVENTION DEVELOPMENT AND TESTING. TO INVESTIGATE PERSONALIZED INTERVENTION STRATEGIES ACROSS DISEASE PROGRESSION AND DEVELOPMENT, AND, TO DEVELOP AND REFINE COMPUTATIONAL APPROACHES AND RESEARCH DESIGNS THAT CAN BE USED TO INFORM AND TEST PERSONALIZED INTERVENTIONS. TO DEVELOP AND TEST APPROACHES FOR ADAPTING, COMBINING, AND SEQUENCING INTERVENTIONS TO ACHIEVE THE GREATEST IMPACT ON THE LIVES AND FUNCTIONING OF PERSONS SEEKING CARE, TO CONDUCT EFFICIENT PRAGMATIC TRIALS THAT EMPLOY NEW TOOLS TO RAPIDLY IDENTIFY, ENGAGE, ASSESS, AND FOLLOW PARTICIPANTS IN THE CONTEXT OF ROUTINE CARE, AND, TO ENHANCE THE PRACTICAL RELEVANCE OF EFFECTIVENESS RESEARCH VIA DEPLOYMENT-FOCUSED, HYBRID, EFFECTIVENESS-IMPLEMENTATION STUDIES. TO EMPLOY ASSESSMENT PLATFORMS WITHIN HEALTHCARE SYSTEMS TO ACCURATELY ASSESS THE DISTRIBUTION AND DETERMINANTS OF MENTAL ILLNESSES AND TO INFORM STRATEGIES FOR IMPROVED SERVICES, TO OPTIMIZE REAL-WORLD DATA COLLECTION SYSTEMS TO IDENTIFY STRATEGIES FOR IMPROVING ACCESS, QUALITY, EFFECTIVENESS, AND CONTINUITY OF MENTAL HEALTH SERVICES, AND, TO COMPARE ALTERNATIVE FINANCING MODELS TO PROMOTE EFFECTIVE AND EFFICIENT CARE FOR INDIVIDUALS WITH SERIOUS EMOTIONAL DISTURBANCES AND SERIOUS MENTAL ILLNESSES. TO STRENGTHEN PARTNERSHIPS WITH KEY STAKEHOLDERS TO DEVELOP AND VALIDATE STRATEGIES FOR IMPLEMENTING, SUSTAINING, AND CONTINUOUSLY IMPROVE EVIDENCE-BASED PRACTICES, TO BUILD MODELS TO SCALE-UP EVIDENCE-BASED PRACTICES FOR USE IN PUBLIC AND PRIVATE PRIMARY CARE, SPECIALTY CARE AND OTHER SETTINGS, AND, TO DEVELOP DECISION-SUPPORT TOOLS AND TECHNOLOGIES THAT INCREASE THE EFFECTIVENESS AND CONTINUOUS IMPROVEMENT OF MENTAL HEALTH INTERVENTIONS IN PUBLIC AND PRIVATE PRIMARY CARE, SPECIALTY CARE, AND OTHER SETTINGS. TO ADAPT, VALIDATE, AND SCALE-UP PROGRAMS CURRENTLY IN USE THAT IMPROVE MENTAL HEALTH SERVICES FOR UNDERSERVED POPULATIONS, TO DEVELOP AND VALIDATE SERVICE DELIVERY MODELS THAT PROVIDE EVIDENCE-BASED CARE FOR INDIVIDUALS THROUGHOUT THE COURSE OF MENTAL ILLNESS, TO DEVELOP AND VALIDATE SYSTEMS-LEVEL STRATEGIES USING TECHNOLOGY AND OTHER APPROACHES, TO IDENTIFY, SUPPORT, AND MONITOR THE EFFECTIVENESS OF EVIDENCE-BASED CARE THROUGHOUT THE COURSE OF ILLNESS, AND, TO DEVELOP AND VALIDATE DECISION-MAKING MODELS THAT BRIDGE MENTAL HEALTH, MEDICAL, AND OTHER CARE SETTINGS TO INTEGRATE THE APPROPRIATE CARE FOR PEOPLE WITH SERIOUS MENTAL ILLNESSES AND COMORBID MEDICAL CONDITIONS.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Boston,
Massachusetts
021142790
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 181% from $3,587,572 to $10,065,985.
The General Hospital Corporation was awarded
CSRP: Suicide Prevention & Research for Healthcare Settings
Project Grant P50MH129699
worth $10,065,985
from the National Institute of Mental Health in August 2023 with work to be completed primarily in Boston Massachusetts United States.
The grant
has a duration of 4 years 9 months and
was awarded through assistance program 93.242 Mental Health Research Grants.
The Project Grant was awarded through grant opportunity Practice-Based Suicide Prevention Research Centers (P50 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 7/3/25
Period of Performance
8/8/23
Start Date
5/31/28
End Date
Funding Split
$10.1M
Federal Obligation
$0.0
Non-Federal Obligation
$10.1M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for P50MH129699
Transaction History
Modifications to P50MH129699
Additional Detail
Award ID FAIN
P50MH129699
SAI Number
P50MH129699-40075276
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75N700 NIH National Institute of Mental Health
Funding Office
75N700 NIH National Institute of Mental Health
Awardee UEI
FLJ7DQKLL226
Awardee CAGE
0ULU5
Performance District
MA-08
Senators
Edward Markey
Elizabeth Warren
Elizabeth Warren
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute of Mental Health, National Institutes of Health, Health and Human Services (075-0892) | Health research and training | Grants, subsidies, and contributions (41.0) | $3,575,395 | 100% |
Modified: 7/3/25